HIV protease inhibitors and hyperlipidemia: A fatty acid connection

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 26, Issue 1, 2006, Pages 7-9

  Spector, Arthur A ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b Bowen Science Building ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERMEDIATE DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEINASE INHIBITOR; RITONAVIR; VERY LOW DENSITY LIPOPROTEIN; FATTY ACID;

ACUTE PANCREATITIS; EDITORIAL; FATTY ACID METABOLISM; HEP 2 CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; LIPID DIET; LIPODYSTROPHY; NONHUMAN; PRIORITY JOURNAL; ANIMAL; ATHEROSCLEROSIS; CHEMICALLY INDUCED DISORDER; METABOLISM; NOTE;

ANIMALS; ATHEROSCLEROSIS; FATTY ACIDS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; HYPERLIPIDEMIAS;

EID: 33644826014     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000198749.28422.29     Document Type: Editorial

References (22)

1. Patella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Statten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-860.
2. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-F58.
3. Stein JH, Klein MA, Bellehumeur JH, McBride PE, Wiebe DA, Otvos JD, Sosman JM. Use of humanimmunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation. 2001;104:257-262.
4. Schillaci G, DeSocio GVL, Pirro M, Savarese G, Mannarino MR, Baldelli F, Stagni G, Mannarino E. Impact of treatment with protease inhibitors on aortic stiffness in adult patients with human immunodeficiency virus infection. Arterioscler Thromb Vasc Biol. 2005;25:2381-2385.
5. Carpentier A, Patterson BW, Uffelman KD, Salit I, Lewis GF. Mechanism of highly active anti-retroviraltherapy-induced hyperlipidemia in HIV-infected individuals. Atherosclerosis. 2005;178:165-172.
6. Riddle TM, Schildmeyer NM, Phan C, Fichtenbaum CJ, Hui DY. The HIV protease inhibitor ritonavir increases lipoprotein production and has no effect on lipoprotein clearance in mice. J Lipid Res. 2002;43:1458-1463.
7. Lenhard JM, Croom DK, Weiel JE, Winegar DA. Protease inhibitors stimulate hepatic triglyceride synthesis. Arterioscler Thromb Vasc Biol. 2000;20:2625-2629.
8. Riddle TM, Kuhel DG, Woolett LA, Fichtenbaum CJ, Hui DY. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory-element binding proteins in the nucleus. J Biol Chem. 2001;276:37514-37519.
9. Liang JS, Distler O, Cooper DA, Jamil H, Deckelbaum RJ, Ginsberg HN, Sturley SL. HIV protease inhibitors protect apolipiprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med. 2001;7:1327-1331.
10. Purnell JQ, Zambon A, Knopp RH, Pizzuti DJ, Achari R, Leonard JM, Locke C, Brunzell JD. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS. 2000;14:51-57.
11. Baril L, Beucler I, Valantin MA, Bruckert E, Bonnefont-Rousselot D, Coutellier A, Caumes E, Katlama C, Bricaire F. Low lipolytic enzyme activity in patients with severe hypertriglyceridemia on highly active antiretroviral therapy. AIDS. 2001;15:415-417.
12. Stein JH, Merwood MA, Bellehumeur JB, McBride PE, Wiebe DA, Sosman JM. Postprandial lipoprotein changes in patients taking antiretroviral therapy for HIV infection. Arterioscler Thromb Vasc Biol. 2005;25:399-405.
13. den Boer MAM, Berbée JFP, Reiss P, van der Valk M, Voshol PJ, Kuipers F, Havekes LM, Rensen PCN, Romijn JA. Ritonavir impairs LPL-mediated lipolysis and decreases uptake of fatty acids in adipose tissue. Arterioscler Thromb Vasc Biol. 2006;26:124-129.
14. Sullivan AK, Feher MD, Nelson MR, Gazzard BG. Marked hypertriglyceridaemia associated with ritonavir therapy. AIDS. 1998;12:1393-1394.
15. Spector AA. Fatty acid binding to plasma albumin. J Lipid Res. 1975;16:165-179.
16. Hamilton JA, Johnson RA, Corkey B, Kamp F. Fatty acid transport. The diffusion mechanism in model and biological membranes. J Molec Neurosci. 2001;16:99-108.
17. Glatz JFC, Luiken JJFP, Bonen A. Involvement of membrane-associated proteins in the acute regulation of cellular fatty acid uptake. J Molec Neurosci. 2001;16:123-132.
18. Veerkamp JH, Zimmerman AW. Fatty acid binding proteins in the nervous system. J Molec Neurosci. 2001;16:133-142.
19. Coburn CT, Hajri T, Ibrahimi A, Abumrad NA. Role of CD36 in membrane transport and utilization of long-chain fatty acids by different tissues. J Molec Neurosci. 2001;16:117-121.
20. Serghides L, Nathoo S, Walmsley S, Kain KC. CD36 deficiency induced by antiviral therapy. AIDS. 2002;16:353-358.
21. Goudriaan JR, den Boer MA, Rensen PC, Febbraio M, Kuipers F, Romijn JA, Havekes LM, Voshol PJ. CD36 deficiency in mice impairs lipoprotein lipase-mediated triglyceride clearance. J Lipid Res. 2005;46:2175-2181.
22. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HTV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia and insulin resistance. Lancet. 1998;351:1881-1883.